drugset / Trial / NCT03247140

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

NCT03247140

Phase 1 Completed 40 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Timeline

Start
2017-06-10
Primary completion
2017-08-07
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject JLP-1401 Unknown
Subject Rosuvastatin Small molecule 20 mg
Subject Telmisartan Other / unclassified 40 mg